Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. , based in the US, focuses on developing innovative drug delivery systems for chronic diseases, aiming to improve patient outcomes through advanced therapeutic solutions. Founded in 1997 and headquartered in Boston, US, Intarcia Therapeutics, Inc. specializes in drug delivery systems.

The company has undergone significant developments in its business strategy to enhance its therapeutic offerings. Kurt Graves serves as the CEO. Most recently, Intarcia completed a VENTURE DEBT funding round of USD 125. 37 mn, raising a total of USD 48.

93 mn to date across 29 deals, with the latest deal occurring on August 28, 2023. Intarcia Therapeutics, Inc. is known for its advanced drug delivery systems designed to improve the treatment of chronic diseases. The company offers innovative solutions that facilitate the effective administration of therapies, focusing on enhancing patient adherence and outcomes.

Intarcia generates revenue through the sale of its proprietary drug delivery systems and related services. The company's revenue model is built on direct sales of its products and ongoing collaborations with healthcare systems to implement its solutions. In August 2023, Intarcia Therapeutics was acquired by i2o Therapeutics, Inc. , a portfolio company of Sanofi Ventures and JDRF T1D Fund.

This acquisition is expected to support the integration of Intarcia's innovative drug delivery systems into broader therapeutic strategies. Future plans include expanding the reach of its products into new markets and enhancing its pipeline with additional therapies designed for chronic conditions.